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1 Introduction
Gastric cancer is still a major world problem, ranking fifth for
incidence and third for cancer-related mortality worldwide in
the latest published global cancer statistics [1]. Even though
early recognition and treatment is possible, most cases are di-
agnosed at a late stage and thus most patients with a diagnosis
of gastric cancer die of the disease [1]. Screening and surveil-
lance of people at risk may decrease gastric cancer mortality
by allowing early detection and treatment, often by endoscopy
instead of more invasive surgery, and have therefore been re-
commended [2, 3].
In 2012, the European Society of Gastrointestinal Endoscopy
(ESGE), the Sociedade Portuguesa de Endoscopia Digestiva
(SPED), the European Helicobacter and Microbiota Study Group
(EHMSG), and the European Society of Pathology (ESP) pro-
duced the first international guideline on the management of
precancerous conditions and lesions in the stomach (MAPS) [4,
5]. Its recommendations were then presented in various coun-
tries, and were adapted and translated in some. Moreover, the
MAPS Guideline was incorporated into ESGE guidelines on qual-
ity parameters for upper gastrointestinal (GI) endoscopy [6].
This document aims to update the first MAPS guideline (re-
ferred to here as MAPS I) and to summarize current evidence on
the management of patients with precancerous conditions and
lesions, focusing on the evidence published after 2010.
MAIN RECOMMENDATIONS
Patients with chronic atrophic gastritis or intestinal meta-
plasia (IM) are at risk for gastric adenocarcinoma. This
underscores the importance of diagnosis and risk stratifica-
tion for these patients. High definition endoscopy with
chromoendoscopy (CE) is better than high definition
white-light endoscopy alone for this purpose. Virtual CE
can guide biopsies for staging atrophic and metaplastic
changes and can target neoplastic lesions. Biopsies should
be taken from at least two topographic sites (antrum and
corpus) and labelled in two separate vials. For patients
with mild to moderate atrophy restricted to the antrum
there is no evidence to recommend surveillance. In patients
with IM at a single location but with a family history of gas-
tric cancer, incomplete IM, or persistent Helicobacter pylori
gastritis, endoscopic surveillance with CE and guided biop-
sies may be considered in 3 years. Patients with advanced
stages of atrophic gastritis should be followed up with a
high quality endoscopy every 3 years. In patients with dys-
plasia, in the absence of an endoscopically defined lesion,
immediate high quality endoscopic reassessment with CE
is recommended. Patients with an endoscopically visible le-
sion harboring low or high grade dysplasia or carcinoma
should undergo staging and treatment. H. pylori eradication
heals nonatrophic chronic gastritis, may lead to regression
of atrophic gastritis, and reduces the risk of gastric cancer
in patients with these conditions, and it is recommended.
H. pylori eradication is also recommended for patients with
neoplasia after endoscopic therapy. In intermediate to high
risk regions, identification and surveillance of patients with
precancerous gastric conditions is cost-effective.
SOURCE AND SCOPE
This Guideline is an official statement of the European
Society of Gastrointestinal Endoscopy (ESGE), the Euro-
pean Helicobacter and Microbiota Study Group (EHMSG),
the European Society of Pathology (ESP), and the Socie-
dade Portuguesa de Endoscopia Digestiva (SPED). Based
on new evidence, it makes recommendations on the diag-
nostic assessment and management of individuals with
atrophic gastritis, intestinal metaplasia and dysplasia of
the stomach, updating the 2012 MAPS guideline.
ABBREVIATIONS
AGREE Appraisal of Guidelines for Research and
Evaluation
AUC area under the curve
CE chromoendoscopy
CI confidence interval
COX cyclo-oxygenase
EGC early gastric cancer
EHMSG European Helicobacter and Microbiota Study
Group
ESD endoscopic submucosal dissection
ESGE European Society of Gastrointestinal
Endoscopy
ESP European Society of Pathology
GI gastrointestinal
GRADE Grading of Recommendations Assessment,
Development, and Evaluation
HD-WLE high definition white-light endoscopy
HGD high grade dysplasia
HR hazard ratio
IM intestinal metaplasia
LGD low grade dysplasia
MAPS Management of precancerous conditions and
lesions in stomach
NBI narrow-band imaging
NSAID nonsteroidal anti-inflammatory drug
OLGA Operative Link on Gastritis Assessment
OLGIM Operative Link on Gastritis Assessment based
on Intestinal Metaplasia
OR odds ratio
RCT randomized controlled trial
RR relative risk
SIR standardized incidence ratio
SPED Sociedade Portuguesa de Endoscopia
Digestiva
Guideline
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Scope
Management (diagnostic assessment, treatment, and surveil-
lance) of individuals with atrophic gastritis, intestinal metapla-
sia, and dysplasia of the stomach.
2 Methods
These recommendations were developed according to the Ap-
praisal of Guidelines for Research and Evaluation (AGREE) pro-
cess for the development of clinical practice guidelines [7]. In
October 2016, on behalf of ESGE, EHMSG, ESP, and SPED, the
coordinators of the previous 2012 Guideline (MAPS I) assem-
bled a panel of European gastroenterologists and pathologists
in order to produce an updated guideline, MAPS II.
Working groups were set up to cover the following topics:
(1) Definitions and prevalence; (2) Endoscopic diagnosis;
(3) Biopsies and histology; (4) Noninvasive assessment; (5) Fol-
low-up; (6) Helicobacter pylori treatment; (7) Other therapies;
(8) Management; and (9) Cost-effectiveness. (See online-only
Supplementary material.)
The evidence-based Delphi process was applied to develop
consensus statements. First, key questions were agreed and
statements were proposed by the MAPS II coordinators (P.P.N.
and M.D.R.), considering previous MAPS I statements and po-
tential changes to previous recommendations. Each working
group considered their statements, and changed these accord-
ing to evidence if necessary. A literature search was done using
PubMed (until March 2018) with a focus on articles published
after the MAPS I literature search (November 2010). Each work-
ing group rated the quality level of the available evidence and
the strength of recommendations using the Grading of Recom-
mendations Assessment, Development, and Evaluation
(GRADE) process [8, 9]. The MAPS II coordinators evaluated
and grouped each statement and evidence in a single docu-
ment with all the necessary bibliography. This document was
then sent to every participant and statements were voted
upon online. At this stage, changes were made if necessary and
statements with less than 75% agreement were excluded. A
final version with the consensus recommendations (▶Table 1)
was sent to and approved by every author. Finally, the manu-
script was reviewed by two members of the ESGE Governing
Board and sent for further comments to the National Societies
and Individual Members. Suggestions were considered, and
after agreement on a final version the manuscript was submit-
ted for publication.
3 Definitions and prevention aims
3.1 Gastric carcinogenesis
Intestinal-type gastric adenocarcinoma represents the final
outcome of the inflammation–atrophy–metaplasia–dysplasia–
carcinoma sequence, known as the Correa cascade [10–14].
Chronic atrophic gastritis and intestinal metaplasia (IM) are
considered to be precancerous conditions because they inde-
pendently confer a risk for development of gastric cancer and
constitute the background in which dysplasia and adenocarci-
noma may occur [11, 15–17]. Diverse efforts have been made
to stage or classify individuals according to the severity and/or
extent of these changes. Advanced stages of atrophic gastritis
should be defined as significant (moderate to marked) atrophy
or as IM (as the best and more reliable marker of atrophy) af-
fecting both antral and corpus mucosa.
In MAPS I, the Operative Link on Gastritis Assessment (OLGA),
and Operative Link on Gastritis Assessment based on Intestinal
Metaplasia (OLGIM) systems were proposed for staging of atro-
phy and IM, respectively. A large body of evidence, consolidated
in a recent meta-analysis, is now available ascertaining OLGA/
OLGIM reliability, with minor differences between the two sys-
tems regarding predictive value for gastric cancer risk [18]. A
recent study pointed out that the likelihood for progression to
gastric cancer of high versus low OLGIM stages is two times that
of high versus low OLGA stages [19]. As the diagnosis of atrophic
gastritis needs grading of the severity of gland loss and this
shows poor inter- and intraobserver agreement, we recom-
mend that OLGIM should be preferred whenever the aim is
staging of mucosal changes [19–24]. OLGIM can be widely
applied with higher accuracy and cost-effectiveness, and also
has lower technical requirements regarding orientation of
STATEMENT
1 Patients with chronic atrophic gastritis or intestinal
metaplasia are at risk for gastric adenocarcinoma.
High quality evidence (100% agree [94% strongly or
moderately agree]).
STATEMENT
2 Histologically confirmed intestinal metaplasia is the
most reliable marker of atrophy in gastric mucosa.
High quality evidence (100% agree [100% strongly or
moderately agree]).
RECOMMENDATION
3 Patients with advanced stages of gastritis, that is,
atrophy and/or intestinal metaplasia affecting both antral
and corpus mucosa, should be identified as they are con-
sidered to be at higher risk for gastric adenocarcinoma.
Moderate quality evidence, strong recommendation
(94% agree [94% strongly or moderately agree]).
RECOMMENDATION
4 High grade dysplasia and invasive carcinoma should be
regarded as the outcomes to be prevented when patients
with chronic atrophic gastritis or intestinal metaplasia are
managed.
Moderate quality evidence, strong recommendation
(100% agree [100% strongly or moderately agree]).
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▶Table 1 Management of epithelial precancerous conditions and lesions in the stomach (MAPS) Guidelines: summary of all MAPS I and MAPS II
recommendations. Changes from MAPS I (new or modified recommendations) are shown in bold.
MAPS I MAPS II (in bold if modified)
Definitions and prevention aims
1 Patients with chronic atrophic gastritis or intestinal metaplasia should
be considered to be at higher risk for gastric adenocarcinoma
1 Patients with chronic atrophic gastritis or intestinal metaplasia are
at risk for gastric adenocarcinoma (high quality evidence)
2 Histologically confirmed intestinal metaplasia is the most reliable
marker of atrophy in gastric mucosa (high quality evidence)
3 Patients with advanced stages of gastritis, that is atrophy and/or
intestinal metaplasia affecting both antral and corpus mucosa,
should be identified as they are considered to be at higher risk for
gastric adenocarcinoma (moderate quality evidence, strong
recommendation)
2 High grade dysplasia and invasive carcinoma should be regarded as
the outcomes to be prevented when patients with chronic atrophic
gastritis or intestinal metaplasia are managed
4 High grade dysplasia and invasive carcinoma should be regarded as
the outcomes to be prevented when patients with chronic atrophic
gastritis or intestinal metaplasia are managed (moderate quality
evidence, strong recommendation)
3 Patients with endoscopically visible high grade dysplasia or carcinoma
should undergo staging and adequate management
5 Patients with an endoscopically visible lesion harboring low or
high grade dysplasia or carcinoma should undergo staging and
treatment (high quality evidence, strong recommendation)
Diagnosis and staging
4 Conventional white light endoscopy cannot accurately differentiate
and diagnose preneoplastic gastric conditions
5 Magnification chromoendoscopy and narrow band imaging (NBI),
with or without magnification, improve the diagnosis of gastric
preneoplastic conditions/lesions
6 High definition endoscopy with chromoendoscopy (CE) is better
than high definition white-light endoscopy alone for the diagnosis
of gastric precancerous conditions and early neoplastic lesions
(high quality evidence)
6 Within this context, diagnostic upper gastrointestinal endoscopy
should include gastric biopsies sampling
7Whenever available and after proper training, virtual CE, with or
without magnification, should be used for the diagnosis of gastric
precancerous conditions, by guiding biopsy for staging atrophic
and metaplastic changes and by helping to target neoplastic lesions
(moderate quality evidence, strong recommendation)
7 Atrophic gastritis and intestinal metaplasia are often unevenly distri-
buted throughout the stomach. For adequate staging and grading of
gastric precancerous conditions, at least four non-targeted biopsies of
two topographic sites (at the lesser and greater curvature, from both
the antrum and the corpus) should be taken and clearly labelled in
separate vials; additional target biopsies of lesions should be taken
8 For adequate staging of gastric precancerous conditions, a first-
time diagnostic upper gastrointestinal endoscopy should include
gastric biopsies both for Helicobacter pylori infection diagnosis and
for identification of advanced stages of atrophic gastritis (moderate
quality evidence, strong recommendation)
9 Biopsies of at least two topographic sites (from both the antrum
and the corpus, at the lesser and greater curvature of each) should
be taken and clearly labelled in two separate vials. Additional
biopsies of visible neoplastic suspicious lesions should be taken
(moderate quality evidence, strong recommendation)
8 Systems for histopathological staging (e. g. operative link for gastritis
assessment [OLGA] and operative link for gastric intestinal metaplasia
[OLGIM] assessment) may be useful for categorization of risk of
progression to gastric cancer
10 Systems for histopathological staging (e. g. Operative Link on
Gastritis Assessment [OLGA] and Operative Link on Gastric Intesti-
nal Metaplasia [OLGIM] assessment) can be used to identify patients
with advanced stages of gastritis. If these systems are used to
stratify patients, additional biopsy of the incisura should be consid-
ered (moderate quality evidence, weak recommendation)
9 Serum pepsinogen levels can predict extensive atrophic gastritis
10 In patients with low pepsinogen test levels, H. pylori serology may be
useful for further detection of high risk individuals
11 Low pepsinogen I serum levels or/and low pepsinogen I/II ratio
identify patients with advanced stages of atrophic gastritis and
endoscopy is recommended for these patients, particularly if
H. pylori serology is negative (moderate quality evidence, strong
recommendation)
11 Family history of gastric cancer should be taken into account in the
follow-up of precancerous conditions
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▶Table 1 (Continuation)
MAPS I MAPS II (in bold if modified)
12 Even though diverse studies assessed age, gender, and H. pylori viru-
lence factors as well as host genetic variations, no clinical recommen-
dations can be made for targeted management based on these factors
with regard to diagnosis and surveillance
12 Even though diverse studies assessed age, gender, and H. pylori viru-
lence factors, as well as host genetic variations, no clinical recommen-
dations regarding diagnosis and surveillance can be made for targeted
management based on these factors (low quality evidence, weak
recommendation)
Surveillance
13 Patients with low grade dysplasia in the absence of an endoscopically
defined lesion should receive follow-up within 1 year after diagnosis. In
the presence of an endoscopically defined lesion, endoscopic resection
should be considered, to obtain a more accurate histological diagnosis
13 In patients with dysplasia in the absence of an endoscopically
defined lesion immediate high quality endoscopic reassessment
with CE (virtual or dye-based) is recommended. If no lesion is
detected in this high quality endoscopy, biopsies for staging of
gastritis (if not previously done) and endoscopic surveillance
within 6 months (if high grade dysplasia) to 12 months (if low grade
dysplasia) are recommended (low quality evidence, strong
recommendation)
14 For patients with high grade dysplasia in the absence of endoscopic-
ally defined lesions, immediate endoscopic reassessment with extensive
biopsy sampling and surveillance at 6-month to 1-year intervals is
indicated
15 For those patients with mild to moderate atrophy/intestinal meta-
plasia restricted to the antrum there is no evidence to recommend
surveillance
14 For patients with mild to moderate atrophy restricted to the antrum
there is no evidence to recommend surveillance (moderate quality evi-
dence, strong recommendation)
15 Patients with IM at a single location have a higher risk of gastric
cancer. However, this increased risk does not justify surveillance in
most cases, particularly if a high quality endoscopy with biopsies
has excluded advanced stages of atrophic gastritis (moderate quali-
ty evidence, strong recommendation)
16 In patients with IM at a single location but with a family history
of gastric cancer, or with incomplete IM, or with persistent H. pylori
gastritis, endoscopic surveillance with chromoendoscopy and
guided biopsies in 3 years’ time may be considered (low quality
evidence, weak recommendation)
16 Endoscopic surveillance should be offered to patients with extensive
atrophy and/or intestinal metaplasia (i. e., atrophy and/or intestinal
metaplasia in the antrum and corpus)
17 Patients with extensive atrophy and/or intestinal metaplasia should
receive follow-up every 3 years after diagnosis
17 Patients with advanced stages of atrophic gastritis (severe
atrophic changes or intestinal metaplasia in both antrum and
corpus, OLGA/OLGIM III/IV) should be followed up with a high
quality endoscopy every 3 years (low quality evidence, strong
recommendation)
18 Patients with advanced stages of atrophic gastritis and with a
family history of gastric cancer may benefit from a more intensive
follow-up (e. g. every 1–2 years after diagnosis) (low quality
evidence, weak recommendation)
19 Patients with autoimmune gastritis may benefit from endo-
scopic follow-up every 3–5 years (low quality evidence, weak
recommendation)
Therapy
18 H. pylori eradication heals nonatrophic chronic gastritis and it may
lead to partial regression of atrophic gastritis
20 H. pylori eradication heals nonatrophic chronic gastritis, may lead
to regression of atrophic gastritis, and reduces the risk of gastric
cancer in patients with nonatrophic and atrophic gastritis, and,
therefore, it is recommended in patients with these conditions
(high quality evidence, strong recommendation)
19 In patients with intestinal metaplasia, H. pylori eradication does not
appear to reverse intestinal metaplasia but it may slow progression to
neoplasia, and therefore it is recommended
21 In patients with established IM, H. pylori eradication does not ap-
pear to significantly reduce the risk of gastric cancer, at least in the
short term, but reduces inflammation and atrophy and, therefore, it
should be considered (low quality evidence, weak recommendation)
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biopsy samples [23]. OLGIM III and IV stages may thus identify
patients at a higher risk for gastric cancer [18, 19].
Gastric dysplasia represents the penultimate stage of the
gastric carcinogenesis sequence. It is defined as histologically
unequivocal neoplastic epithelium without evidence of tissue
invasion, and is thus a direct neoplastic precancerous lesion
[25]. The World Health Organization (WHO) has reiterated the
classification of dysplasia/intraepithelial neoplasia [26]:
▪ Intraepithelial neoplasia/dysplasia comprises unequivocally
epithelial and neoplastic proliferations characterized by
variable cellular and architectural atypia, but without con-
vincing evidence of invasion.
▪ Low grade intraepithelial neoplasia/dysplasia shows minimal
architectural disarray and only mild to moderate cytological
atypia.
▪ High grade intraepithelial neoplasia/dysplasia comprises neo-
plastic cells that are usually cuboidal, rather than columnar,
with a high nucleus-to-cytoplasm ratio, prominent ampho-
philic nucleoli, more pronounced architectural disarray, and
numerous mitoses, which can be atypical. Importantly, the
nuclei frequently extend into the luminal aspect of the cell,
and nuclear polarity is usually lost. Most patients harboring
lesions classified as high grade dysplasia (HGD) are at high
risk for either synchronous invasive carcinoma or its rapid
development.
▪ Intramucosal invasive neoplasia/intramucosal carcinoma de-
fines carcinomas that invade the lamina propria and are dis-
tinguished from intraepithelial neoplasia/dysplasia not only
by desmoplastic changes that can be minimal or absent, but
also by distinct structural anomalies, such as marked glan-
dular crowding, excessive branching, budding, and fused or
cribriform glands. The diagnosis of intramucosal carcinoma
means that there is an increased risk of lymphatic invasion
and lymph node metastasis, although with certain features
this risk is absent or minimal.
Guidelines for endoscopic treatment of early gastric cancer
(EGC) are beyond the scope of this manuscript but can be found
in published ESGE guidelines [2, 3].
3.2 Gastric precancerous and early cancer lesions
In the MAPS I Guideline, we recommended that “Patients
with endoscopically visible high grade dysplasia or carcinoma
should undergo staging and adequate management.” However,
several studies have shown that low grade dysplasia (LGD) also
has a real potential for malignancy and, even more importantly,
visible lesions with LGD on biopsy may in fact already be malig-
nant lesions. Moreover, some biopsies may be negative for dys-
plasia in the face of a true neoplastic lesion [27]. In a Western
endoscopic submucosal dissection (ESD) series, there was a his-
tological upstaging after resection for 33% of the lesions [28].
Similarly, an Eastern study that analyzed 1850 lesions, focusing
on the discrepancy between endoscopy biopsies and endo-
scopic resection specimens, concluded that the overall discre-
pancy rate was 32% [27]. A meta-analysis that specifically in-
vestigated the upstaging of gastric LGD after endoscopic
▶Table 1 (Continuation)
MAPS I MAPS II (in bold if modified)
20 H. pylori eradication is recommended for patients with previous
neoplasia after endoscopic or surgical therapy
22 H. pylori eradication is recommended for patients with gastric
neoplasia after endoscopic therapy (high quality evidence, strong
recommendation)
21 Currently, the use of cyclo-oxgenase-2 (COX-2) inhibitors cannot be
supported as an approach to decrease the risk of progression of gastric
precancerous lesions
23 Even though cyclo-oxygenase (COX)-1 or COX-2 inhibitors may
slow progression of gastric precancerous conditions, they cannot be
recommended specifically for this purpose (low quality evidence,
weak recommendation)
22 The use of dietary supplementation with antioxidants (ascorbic acid
and betacarotene) cannot be supported as a therapy to reduce the
prevalence of atrophy or intestinal metaplasia
24 Low dose daily aspirin may be considered for prevention of vari-
ous cancers, including gastric cancer, in selected patients (moderate
quality evidence, weak recommendation)
Cost-effectiveness
23 After endoscopic resection of early gastric cancer, H. pylori eradica-
tion is cost-effective
25 In intermediate to high risk regions, identification and surveil-
lance of patients with precancerous gastric conditions is cost-
effective (moderate quality evidence)
24 Currently available evidence does not allow an accurate estimation
of the cost-effectiveness of surveillance for premalignant gastric condi-
tions worldwide
RECOMMENDATION
5 Patients with an endoscopically visible lesion harboring
low or high grade dysplasia or carcinoma should undergo
staging and treatment.
High quality evidence, strong recommendation (94%
agree [94% strongly or moderately agree]).
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resection found that this happens in 25% of lesions, with 7%
being upstaged to malignant [29]. Taking all this evidence
together, we can conclude that endoscopic biopsies are insuffi-
cient for correct diagnosis of visible gastric lesions and that an
endoscopically visible lesion with any neoplastic change should
be considered for treatment.
4 Diagnosis and staging
4.1 Endoscopy
Classical studies of conventional white-light endoscopy
(WLE) showed that the correlation between histological and
endoscopic findings for the diagnosis of gastric precancerous
conditions was poor [30–34]. However, recent studies with
high definition WLE (HD-WLE) presented promising results.
For preneoplastic conditions, a cross-sectional study showed
that HD-WLE had a global accuracy of 88% for the diagnosis of
IM with a sensitivity of 75% and specificity of 94% [35]. In a real-
time multicenter prospective study, the global accuracy of HD-
WLE was 83%, with a specificity of 98% for IM but with only 53%
sensitivity [36]. These results were confirmed in another multi-
center prospective study, that showed a 98% specificity for IM
but again with a low sensitivity of 59% [37]. For the diagnosis of
neoplastic lesions these two studies showed low sensitivities of
74% and 29%, respectively, although the specificities were
higher than 95% [36, 37]. HD-WLE with magnification may im-
prove these results; however, the data are too scarce to provide
definitive conclusions [38–40]. So, even though these results
for HD-WLE are satisfactory for IM and for early neoplastic le-
sions they are far from perfect, particularly regarding the sensi-
tivity in the diagnosis of these lesions.
Conventional CE with application of dyes (indigo carmine,
methylene blue, acetic acid, or hematoxylin) has consistently
been associated with the detection of gastric preneoplastic or
neoplastic conditions or lesions with high accuracy [41–45].
In a recently published meta-analysis including 10 studies, 699
patients, and 902 lesions, the pooled sensitivity, specificity, and
area under the curve (AUC) of dye-CE were 0.90 (95% confi-
dence interval [CI] 0.87–0.92), 0.82 (95%CI 0.79–0.86), and
0.95, respectively, these results being significantly better than
WLE alone (risk difference of 0.36 for neoplasia and 0.17 for
premalignant conditions) [46]. However, dye-CE is cumber-
some and significantly lengthens endoscopic procedures. This
favors virtual CE which is available at the touch of a button.
Several studies focused on the role of virtual CE in the diag-
nosis of gastric precancerous conditions. A systematic review
showed that most studies addressed narrow-band imaging
(NBI) (mainly with magnification). The pooled sensitivity and
specificity for the diagnosis of IM were 86% and 77%, and for
dysplasia/early cancer these values were 90% and 83%, respec-
tively [47]. However, the authors concluded that few studies
addressed interobserver reliability and that there was no valida-
ted classification. Other investigators evaluated all the NBI pat-
terns previously described, and created and validated a simpli-
fied NBI (without magnification) classification using only repro-
ducible NBI features (▶Fig. 1) [48]. The global accuracy for the
diagnosis of IM was 84% and for dysplasia it was 95%. However,
these results clearly depend on training and are better with ex-
perienced endoscopists [48, 49]. External validation of this clas-
sification in a prospective multicenter study involving five inter-
national Western centers (some using near-focus and second-
generation NBI) showed a sensitivity and specificity of 87%
and 97% for the diagnosis of IM and 92% and 99% for the
diagnosis of dysplasia [36]. The diagnostic accuracy rate was
of 94% (11% higher than HD-WLE), with the greatest advan-
tage of NBI over or after WLE being sensitivity for detecting IM
(87% vs. 53%, P<0.001) and sensitivity for neoplasia (92% vs.
74%) [36]. Altogether these results supported the ESGE Tech-
nology Review on advanced imaging which suggested this clas-
sification as the one to be used in this context [50].
Other studies comparing HD-WLE to NBI consistently
showed better results with NBI for detecting both IM and EGC.
A large multicenter prospective randomized study reached the
same conclusions this time in an Eastern population. Again,
even though specificities for IM and cancer were the same, the
sensitivities for IM (92% vs. 59%) and particularly for cancer
(100% vs. 29%) were much higher with second-generation NBI
when compared to HD-WLE [37]. In an Indian randomized pro-
spective crossover study the conclusions were very similar re-
garding IM, with the frequency of IM detection by NBI being
significantly higher than by WLE (P=0.001) [51].
We can conclude that NBI is better than HD-WLE for the de-
tection and diagnosis of IM, but is it better than standard non-
targeted biopsy sampling? In a comparative study including
119 patients, the overall sensitivity, specificity, and accuracy
of WLE nontargeted biopsies taken according to the Sydney-
Houston protocol were compared with NBI-guided biopsies.
For predicting atrophy, the WLE nontargeted biopsies vs. NBI
results were 86% vs. 62%, 100% vs. 97%, and 93% vs. 80%,
respectively; for IM they were 80% vs. 72%, 100% vs. 93%, and
90% vs. 82%. These results were slightly better for nontargeted
STATEMENT
6 High definition endoscopy with chromoendoscopy (CE)
is better than high definition white-light endoscopy alone
for the diagnosis of gastric precancerous conditions and
early neoplastic lesions.
High quality evidence (94% agree [94% strongly or mod-
erately agree.
RECOMMENDATION
7 Whenever available and after proper training, virtual
CE, with or without magnification, should be used for
the diagnosis of gastric precancerous conditions, by guid-
ing biopsy for staging atrophic and metaplastic changes
and by helping to target neoplastic lesions.
Moderate quality evidence, strong recommendation
(94% agree [94% strongly or moderately agree]).
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protocol biopsies. This was only significant with respect to the
detection of atrophy (P=0.03) and not for IM or dysplasia [52].
A prospective blinded trial detected higher proportions of pa-
tients with IM by NBI-guided (65%) or WLE nontargeted map-
ping (76%) versus HD-WLE-guided biopsies (29%; P<0.005 for
both comparisons). In this study the best results would have
been obtained by combining NBI with mapping (detection of
100% of patients with IM and 95% of areas with IM), with NBI
identifying different patients and sites with IM that would not
have been detected by mapping alone [53]. We can firstly con-
clude that random biopsies may detect some cases that are not
detected by NBI alone. However, most of these cases will have
mild/moderate atrophy (that has no validated NBI pattern) or
mild/focal IM that does not require surveillance. In fact, it has
been shown that, with an appropriately experienced operator,
second-generation NBI may detect almost every case of exten-
sive atrophy/IM without the need of biopsies [54]. Secondly, in
expert hands, NBI-guided biopsies may increase the diagnostic
yield of mapping biopsies. When the two modalities are com-
bined, they will detect almost all cases of gastric precancerous
conditions. Finally, it seems clear that atrophic changes and IM
are unevenly distributed throughout the stomach. In this con-
text, an Endoscopic Grading of Gastric Intestinal Metaplasia
(EGGIM) system has been proposed, and in theory it may allow
better staging of gastritis than histology alone since it takes
into account complete assessment of the gastric mucosa [36].
However, future studies are needed to validate the EGGIM clas-
sification before routine clinical application.
Regarding EGC diagnosis, other investigators showed that
magnifying NBI was better than HD-WLE with an accuracy of
90% (vs. 65%, P<0.001) [55]. A recent meta-analysis also con-
cluded that magnifying NBI is better than WLE alone with an
AUC of 0.96 for diagnosing EGC [56]. Two studies (one Eastern,
the other Western) compared NBI without magnification to HD-
WLE and suggested increased diagnostic accuracy of NBI over
HD-WLE alone [36, 37]. In one study, 7 EGC lesions were detect-
ed by NBI, but only 2 by HD-WLE [37]. In another study, 5 EGC
lesions were misdiagnosed by WLE alone, with 2 of them being
only seen with NBI [36]. Even though both studies were under-
powered for this purpose, they support the estimate that use of
only HD-WLE may miss almost 10% of neoplastic lesions. This
estimate is in accordance with the 10% miss rate for gastric
cancer observed during upper GI endoscopy [57, 58]. Thus,
NBI outperforms HD-WLE for diagnosis and characterization
and it may increase detection of EGC lesions.
▶ Fig. 1 Simplified narrow-band imaging (NBI) classification for the endoscopic diagnosis of gastric precancerous conditions and lesions.
a Antrum (upper panel) and body (lower panel): normal gastric mucosa. A regular and circular/oval mucosal pattern with regular thin/peripheral
(body) or thick/central (antrum) vessels is highly predictive of a normal mucosa. b Intestinal metaplasia (IM). Regular vessels with ridge/tubular
or tubulovillous glands, particularly with a light blue crest, are highly suggestive of IM. In general, these areas of mucosa alternate with areas of
normal but atrophic mucosa. c Dysplasia/carcinoma. Irregular vessels and glands (upper panel, high grade dysplasia lesion), or absent glands
with complete architectural loss of the mucosal and vascular pattern (lower panel, intramucosal adenocarcinoma) predict neoplastic changes of
the mucosa.
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There is less evidence to support other methods of virtual CE
such as i-Scan digital contrast and flexible spectral imaging col-
or enhancement (FICE). There are currently insufficient data to
recommend routine clinical use of these techniques, even
though in theory and after proper training they could have
similar applications [47, 59]. A few prospective studies suggest-
ed that blue laser imaging may achieve similar results to NBI
[60–62]. Other emerging technologies, such as confocal endo-
microscopy, endocytoscopy, Raman spectroscopy, and polari-
metry, may have a future role but at this stage cannot be re-
commended for routine clinical use [59].
4.2 Biopsy sampling
Considering that most endoscopists are not yet familiar with
advanced imaging patterns, at present we cannot recommend
exclusively endoscopic staging of gastritis without biopsies.
However, current evidence suggests that CE-targeted biopsies
plus mapping biopsies are the best way of detecting most cases
of advanced gastritis. For these reasons we recommend that,
when available, CE should be used for targeted biopsies.
When CE is not available (or the endoscopist doubts the ad-
vanced imaging diagnosis), the number of biopsies needed for
correct staging is debated. More biopsies will allow better stag-
ing. However, in clinical practice more biopsies mean more
time and higher procedure costs. In the MAPS I Guideline, we
recommended at least two biopsies from the antrum and two
from the corpus, and the lack of obligatory biopsy of the inci-
sura was a matter of some controversy. In fact, the incisura
may be the anatomical location with the highest incidence and
severity of IM [63–65]. This is used to support an additional
biopsy of the incisura. The updated Sydney system is the most
widely accepted protocol for the classification and grading of
gastritis. It recommends at least five biopsies: two from the an-
trum (from the greater and lesser curvature, 3 cm from the py-
lorus); one from the incisura; and two from the body (from the
lesser curvature, 4 cm proximal to the incisura, and from the
greater curvature, middle). This differed from the initial Sydney
protocol that recommended only two biopsies from the corpus
and two from the antrum [20]. However, the need to sample
the incisura was based mostly on the notion that atrophic/me-
taplastic changes appear first in the incisura even though there
were no data suggesting a clinical benefit. In this regard a large
study, published after the MAPS I Guideline, evaluated 400738
biopsy sets and found that compliance with the original Sydney
system (two antrum, two corpus) had the highest yield for the
diagnosis of H. pylori infection and IM when compared with all
other biopsy strategies [66]. More biopsies or inclusion of an in-
cisura biopsy yielded minimal additional diagnostic information
with more costs. Some studies, published after MAPS I, specifi-
cally addressed the benefit of incisura biopsy sampling. The in-
clusion of incisura biopsy increased the proportion of patients
classified with high risk stages (OLGA III/IV or OLGIM III/IV) in
three studies (two European studies including nonselected po-
pulations [65, 67] and one Korean study in high risk patients
[64]). All found that the incisura biopsy increased the propor-
tion of patients with high risk stages. Considering the two Euro-
pean studies from nonselected populations together, without
the incisura biopsy, there was a downgrading from high risk
OLGA stages to low risk OLGA in 14/1048 patients (absolute dif-
ference 1.33%) and from high risk OLGIM to low risk OLGIM in
13/1048 patients (absolute difference 1.24%). This translates
into a number needed to treat of 75–80, meaning that one in
75–80 patients will not be correctly included in a high risk
group if incisura biopsy is not performed. Another European
study evaluated classification systems in a high risk population
(first-degree relatives of early onset gastric cancer patients)
using OLGA and OLGIM staging systems that were modified by
exclusion of the incisura biopsy, and demonstrated an overall
15% and 30% downgrade of staging in comparison with the ori-
ginal OLGA/OLGIM systems. In high risk stages, the downgrade
of staging was less pronounced (5%) for both modified staging
systems in comparison with the original OLGA system [68].
Another study comparing different biopsy protocols reported
that biopsy of the incisura did not provide additional benefit as
the prevalence of IM in the incisura was similar to that in other
biopsy sites, although the impact of incisura biopsies in high
risk phenotypes was not assessed [66].
RECOMMENDATION
10 Systems for histopathological staging (e. g. OLGA and
OLGIM assessment) can be used to identify patients with
advanced stages of atrophic gastritis. If these systems are
used to stratify patients, additional biopsy of the incisura
should be considered.
Moderate quality evidence, weak recommendation (88%
agree [58% strongly or moderately agree]).
RECOMMENDATION
9 Biopsies of at least two topographic sites (from both
the antrum and the corpus, at the lesser and greater cur-
vature of each) should be taken and clearly labelled in two
separate vials. Additional biopsies of visible neoplastic
suspicious lesions should be taken.
Moderate quality evidence, strong recommendation
(94% agree [82% strongly or moderately agree]).
RECOMMENDATION
8 For adequate staging of gastric precancerous condi-
tions, a first-time diagnostic upper gastrointestinal
endoscopy should include gastric biopsies both for
H. pylori infection diagnosis and for identification of ad-
vanced stages of atrophic gastritis
Moderate quality evidence, strong recommendation
(88% agree [77% strongly or moderately agree]).
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In summary, this small additional yield from an incisura
biopsy needs to be balanced against costs and workload. We
therefore recommend a minimum of two biopsies from the an-
trum and two biopsies from the corpus, noting that adding an
incisura biopsy can be considered in order to maximize the de-
tection of patients with precancerous conditions, especially in
cases where CE is not available to target biopsies. Moreover,
this additional biopsy will allow more precise evaluation of
OLGA and OLGIM stages, that have been proven to correlate
with risk for cancer progression [69–71].
Regarding the number of vials, even though separate vials
may not be required among expert pathologists, as antral and
corpus mucosa can be easily distinguished in the absence of se-
vere atrophic changes, use of a single vial cannot be recom-
mended in all cases. Future studies should evaluate specific
scenarios when antrum, incisura, and corpus samples can be
sent in the same vial.
4.3 Noninvasive assessment
As stated in the MAPS I Guideline, a low pepsinogen I serum
level, a low pepsinogen I/II ratio, or both, are good indicators of
atrophic changes in the gastric mucosa. A 2004 meta-analysis
suggested that pepsinogen I≤50ng/mL and pepsinogen I/II
ratio ≤3 were the best cutoff values for dysplasia diagnosis
[72]. Several articles published after MAPS I confirm levels of
pepsinogens to be good indicators of extensive atrophic gastri-
tis and of gastric cancer [73, 74]. A 2015 meta-analysis on pep-
sinogen tests in gastric cancer and atrophic gastritis suggested
a good correlation between decreased pepsinogen serum levels
and atrophy [75]. In this meta-analysis, the summary sensitivity
and summary specificity for gastric cancer diagnosis were 0.69
(95%CI 0.60–0.76) and 0.73 (95%CI 0.62–0.82), respectively.
Corresponding values for atrophic gastritis diagnosis were 0.69
(95%CI 0.55–0.80) and 0.88 (95%CI 0.77–0.94), respectively.
The AUC for gastric cancer diagnosis was 0.76 (95%CI 0.72–
0.80) and for atrophic gastritis it was 0.85 (95%CI 0.82–0.88).
A Fagan plot indicated that the use of pepsinogen serum levels
could moderately improve the gastric cancer and atrophy de-
tection rate, confirming a moderate efficiency of pepsinogen
serum levels for gastric cancer and atrophic gastritis diagnosis.
In a subgroup analysis the authors concluded that combining
low pepsinogen I level with the pepsinogen I/II ratio is the best
way of detecting gastric cancer (AUC 0.78) and atrophic gastri-
tis (AUC 0.87). However, different cutoff values were used,
although most studies used pepsinogen I < 70ng/mL and pepsi-
nogen I/II ratio < 3 as the best cutoff values. In fact, these are
widely accepted cutoff values for gastric cancer screening in
Japan [76]. The authors concluded that pepsinogen serum lev-
els have a potentially significant role in the identification of po-
pulations at high risk for gastric cancer and could be used for
mass screening. However, they note that there was great
heterogeneity between studies. Moreover, different methods
are used for quantifying levels of pepsinogens and in this
meta-analysis enzyme-linked immunoassay (ELISA) was slightly
superior to the other methods, with this difference possibly in-
ducing heterogeneity [75]. In fact, different methods may be
used for pepsinogen quantification and results may differ be-
tween tests [77]. Therefore, cutoff values validated for a partic-
ular assay should be used, and cannot be generalized to all as-
says.
Other serum molecule levels were studied as markers of gas-
tric atrophy. A 2017 systematic review and meta-analysis fo-
cused on the combination of pepsinogen I/II, gastrin-17, and
anti-Helicobacter antibodies for diagnosing atrophic gastritis
[78]. However, the design of this meta-analysis does not allow
assessment of the individual performance of each marker for
detecting atrophy. Moreover, previously published evidence
demonstrated little yield from adding gastrin-17 to pepsinogen
assessment for detecting atrophy [79]. On the other hand, add-
ing H. pylori serology to pepsinogen level evaluation may help
to detect patients at higher risk of gastric cancer [80, 81]. In a
2014 cohort of 4655 patients followed up for 16 years, there
was a progressive increase in cancer risk, going from those
with no gastritis to those with chronic H. pylori-positive gastritis
without extensive atrophy (H. pylori-positive, normal pepsino-
gen levels; hazard ratio [HR] 8.9, 95%CI 2.7–54.7), to those
with extensive chronic atrophic gastritis (defined by pepsino-
gen I < 70ng/mL and pepsinogen I/II ratio < 3) with H. pylori-po-
sitive serology (HR 17.7, 95%CI 5.4–108), and finally to those
with atrophic gastritis with H. pylori-negative serology, sugges-
tive of extensive IM (HR 69.7, 95%CI 14–503) [81].
Other methods for noninvasive assessment of gastric muco-
sal atrophy, including evaluation of decreased serum ghrelin
[82–84], trefoil factors [85], a panel of microRNAs [86], and
volatile organic compounds in exhaled air [87], have been sug-
gested, with good results. However, the available evidence for
these tests is not sufficient and further studies are required be-
fore they can be recommended for clinical application.
In conclusion, pepsinogen serum levels are currently the
best evaluated noninvasive test for detecting patients with ad-
vanced atrophic gastritis. Low pepsinogen I serum levels, parti-
cularly when associated with H. pylori-negative serological
status, may identify patients at higher risk of gastric cancer to
whom endoscopy should be offered.
RECOMMENDATION
11 Low pepsinogen I serum levels or/and a low pepsino-
gen I/II ratio identify patients with advanced stages of
atrophic gastritis, and endoscopy is recommended for
these patients, particularly if H. pylori serology is
negative.
Moderate quality evidence, strong recommendation
(88% agree [76% strongly or moderately agree]).
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4.4 Additional risk factors
Assuming the gene-environment interaction for gastric can-
cer, multiple risk factors have been linked to the multistep pro-
gression from chronic nonatrophic gastritis to atrophic gastri-
tis, IM, dysplasia, and finally cancer [10].
H. pylori plays a pivotal role in this progression and was clas-
sified as a type 1 carcinogen in 1994 by the WHO [88]. It is
believed that the combination of a virulent organism in a
genetically susceptible host is associated with more severe
chronic inflammation and more rapid progression to gastric
cancer, at least for the Lauren intestinal type [89–91].
Different strains of H. pylori vary in their carcinogenic poten-
tial, with those containing virulence factors, such as the cyto-
toxin-associated antigen (cagA) protein and the vacuolating
toxin A (vacA), inducing a higher degree of inflammation and
increasing the risk for gastric cancer [92–97]. Nevertheless,
there are no studies addressing the clinical usefulness of geno-
typing H. pylori strains with regard to the management and sur-
veillance of gastric precancerous conditions/lesions.
An immense number of studies have addressed the implica-
tions of genes and genetic host variations for gastric carcino-
genesis. The best characterized are those that play a role in
the inflammatory response to H. pylori infection and inflamma-
tion of the gastric mucosa, leading to mucosal atrophy and pro-
gression to cancer. These include host genetic interleukin poly-
morphisms of IL-1B, IL1-receptor antagonist (IL-1RN), IL8, IL10,
and TNF-α [98–104]. However, the heterogeneity of the results
makes it difficult to translate them into recommendations for
daily clinical practice.
5 Surveillance
5.1 Dysplasia
Most routine gastroscopies are performed with standard de-
finition WLE. As we have seen, CE (virtual or dye-based) increas-
es accuracy for detection of dysplasia. A prospective study that
included 20 patients with a diagnosis of HGD or carcinoma,
without visible endoscopic lesions in the index endoscopy,
showed that immediate endoscopic reassessment with high
definition endoscopes and virtual CE allowed the identification
of visible lesions and adequate treatment in 18 patients [105].
Conventional CE also improves the detection of precancerous
conditions and lesions [106]. A systematic review and meta-
analysis reported that approximately 10% of the patients with
a gastric cancer diagnosis had undergone a recent endoscopy
in which the gastric cancer was not diagnosed (because of
both missed endoscopic lesions or nonmalignant pathology di-
agnosis). A recent study also showed that 8.6% of the patients
with EGCs had a simultaneous lesion that was not detected in
the diagnostic endoscopy [57, 107]. The rate of missed lesions
tended to be higher in primary care and screening settings than
in secondary and tertiary care. Another study showed that a
longer endoscopy time (> 7 minutes) was associated with a
higher likelihood of detecting neoplastic lesions (odds ratio
[OR] 3.42, 95%CI 1.25–10.38) [108]. Moreover, a finding of
dysplasia in nontargeted biopsies significantly increases the
risk of gastric cancer, which may be as high as 6% per year
[109]. A recent Swedish study, that to the best of our knowl-
edge is the largest follow-up study to date among patients
with gastric precancerous conditions, suggested a lower risk of
gastric cancer for patients with dysplasia. However, they
excluded the first 2 years of follow-up and concluded that this
might be the reason for the lower risk of gastric cancer since
many lesions might have been there already [110].
“Indefinite for dysplasia/neoplasia” should not be viewed in-
itially as an innocuous diagnosis although in the majority of
patients the prognosis is favorable. Indeed, a study found that
26.8% of resected lesions that had been characterized as inde-
finite for dysplasia/neoplasia in preresection biopsies were in
fact neoplastic (5.0% adenomas and 21.8% EGCs) [111].
Another study found that reassessment of indefinite for dys-
plasia biopsies by three expert gastrointestinal pathologists
RECOMMENDATION
13 In patients with dysplasia in the absence of an endo-
scopically defined lesion immediate high quality endo-
scopic reassessment with CE (virtual or dye-based) is re-
commended. If no lesion is detected in this high quality
endoscopy, biopsies for staging of gastritis (if not pre-
viously done) and endoscopic surveillance within
6 months (if high grade dysplasia) to 12 months (if low
grade dysplasia) are recommended.
Low quality evidence, strong recommendation (88%
agree [88% strongly or moderately agree]).
RECOMMENDATION
12 Even though diverse studies assessed age, gender, and
H. pylori virulence factors, as well as host genetic varia-
tions, no clinical recommendations regarding diagnosis
and surveillance can be made for targeted management
based on these factors.
Low quality evidence, weak recommendation (100%
agree [88% strongly or moderately agree]).
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changed the diagnosis to dysplasia in 11 /46 patients (10 LGD
and 1 HGD) [112].
All of this suggests that patients with diagnoses from non-
targeted biopsies of indefinite for dysplasia, of dysplasia, or of
carcinoma benefit from a careful endoscopic reassessment in
centers with experience in the diagnosis and endoscopic treat-
ment of EGC. We recommend that pathology slides should be
reviewed by an expert GI pathologist and recommend immedi-
ate (as soon as possible) high quality endoscopic reassessment
with CE. If a lesion is seen and the endoscopic assessment sug-
gests dysplasia, we recommend resection without need of fur-
ther biopsies. If endoscopic reassessment with CE does not re-
veal a visible lesion and repeat nontargeted biopsies do not
show dysplasia/neoplasia, then staging the severity and extent
of preneoplastic conditions in such cases can help to define the
surveillance program. A retrospective study of patients with in-
definite for dysplasia lesions at enrollment and OLGA staging,
with a median follow-up of 31 months, did not detect dysplasia
in any patient with OLGA 0 /I/II, while 6 cases of LGD/HGD were
detected in 25 patients with OLGA III/IV during follow-up [113].
With the above considerations in mind, patients with a diag-
nosis of indefinite for dysplasia/neoplasia or of dysplasia/intra-
mucosal carcinoma in random biopsies (i. e., no clear lesion
identified at endoscopy) should be promptly referred to an
expert endoscopy center and have an endoscopic reassessment
with high definition endoscopes and CE (dye or virtual). If no
lesion is identified in this high quality endoscopy, endoscopic
revaluation is recommended at a 6-month (if previous HGD) to
12-month (if previous LGD) interval, with further adjustment
according to the severity and extent of precancerous condi-
tions (▶Fig. 2).
5.2 Atrophic gastritis/intestinal metaplasia
Gastric precancerous conditions are frequent in the general
population (although with wide geographical variability ac-
cording to H. pylori infection prevalence). The annual incidence
of gastric cancer has been reported to be 0.1%–0.25% in pa-
tients with chronic atrophic gastritis and 0.25% in patients
with IM, and may be as high as 1.36% person-year for any gas-
tric neoplasia (including dysplasia and neuroendocrine tumors)
[109, 114]. Cumulative incidences of gastric cancer of 2.4% at
10 years in patients with IM were reported, and a Swedish
study reported a cumulative incidence at 20 years of approxi-
mately 2% in patients with atrophic gastritis and of 2.5% in pa-
tients with IM [110]. A Japanese study found higher cumulative
incidences of gastric cancer at 5 years, reaching 1.9%–10% in
patients with extensive endoscopic atrophy and 5.3%–9.8% in
patients with IM [115].
Surveillance of patients with precancerous conditions allows
the detection of lesions at early stages (with a significant pro-
portion being amenable to endoscopic resection) and was re-
commended in the MAPS I Guideline in patients with extensive
atrophy or IM (in both corpus and antrum). The extent of pre-
neoplastic changes was identified as a risk factor for progres-
sion, as well as family history of gastric cancer and type III
incomplete IM.
Extent and presence of IM Some recent studies confirmed
the presence and extent of IM as risk factors for gastric cancer.
An Italian prospective study found a significantly increased risk
RECOMMENDATION
16 In patients with IM at a single location but with a fam-
ily history of gastric cancer, or with incomplete IM, or
with persistent H. pylori gastritis, endoscopic surveillance
with CE and guided biopsies in 3 years’ time may be
considered.
Low quality evidence, weak recommendation (82% agree
[76% strongly or moderately agree]).
RECOMMENDATION
18 Patients with advanced stages of atrophic gastritis and
with a family history of gastric cancer may benefit from a
more intensive follow-up (e. g. every 1–2 years after
diagnosis).
Low quality evidence, weak recommendation (82% agree
[65% strongly or moderately agree]).
RECOMMENDATION
17 Patients with advanced stages of atrophic gastritis
(severe atrophic changes or IM in both antrum and cor-
pus, OLGA/OLGIM III/IV) should be followed up with a
high quality endoscopy every 3 years.
Low quality evidence, strong recommendation (100%
agree [94% strongly or moderately agree]).
RECOMMENDATION
14 For patients with mild to moderate atrophy restricted
to the antrum there is no evidence to recommend surveil-
lance.
Moderate quality evidence, strong recommendation
(100% agree [100% strongly or moderately agree]).
RECOMMENDATION
15 Patients with IM at a single location have a higher risk
of gastric cancer. However, this increased risk does not
justify surveillance in most cases, particularly if a high
quality endoscopy with biopsies has excluded advanced
stages of atrophic gastritis.
Moderate quality evidence, strong recommendation
(100% agree [82% strongly or moderately agree]).
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of gastric neoplasia in patients with OLGA and OLGIM stages III/
IV at baseline, while extensive atrophy (antrum and corpus) was
also associated with a trend to higher risk of progression al-
though this was not statistically significant on multivariable a-
nalysis (HR 7.2, 95%CI 0.7–6.84) [114]. Extensive IM was also
found to be associated with a higher risk of progression in a US
study [116]. A Japanese study also found that IM in the corpus
(isolated or antrum and corpus) and extensive endoscopic atro-
phy at baseline were independent predictors of gastric cancer
at follow-up [115]. A case-control study found that OLGIM II-IV
(but not OLGA II-IV) and corpus-predominant gastritis were sig-
nificantly more frequent in gastric cancer patients than in con-
trols [117]. Another case-control study found that OLGA III/IV,
OLGIM III/IV, and endoscopically classified moderate-to-severe
atrophy were significantly more frequent in gastric cancer pa-
tients [118]. Another study using endoscopic grading of atro-
phy found that gastric cancer risk was increased in patients
with extensive atrophy (5.33% in patients with atrophy present
in the entire stomach vs. 0% and 0.25% in patients with atrophy
limited to the gastric antrum and atrophy in the incisura or low-
er corpus, respectively) [119]. A Korean study reported that
OLGA III/IV and OLGIM I– IV were independent risk factors for
gastric cancer, especially the intestinal type, showing that
even nonextensive IM may significantly increase the risk of gas-
tric cancer [120]. The adjusted odds ratios for the different
stages were: OLGA III 2.09, OLGA IV 2.04; OLGIM I 2.38, OLGIM
II 2.97, OLGIM III 7.89, OLGIM IV 13.20 (all statistically signifi-
cant). OLGA IV, histological IM, and a higher classification of
endoscopic atrophy were also identified as independent risk
factors in a prospective Korean study with follow-up >3 years
[121]. These studies suggest that the presence of IM (as a sur-
rogate of advanced gastritis) may be of equal or more impor-
tance than the extent of atrophy without IM, since the risk of
gastric cancer was higher with OLGIM I/II than with OLGA III/
IV. This accords with other previous studies that evaluated the
risk of gastric cancer in patients with only atrophy or IM (inde-
pendently of extent), and which showed that the risk of gastric
cancer is higher in IM patients (not considering extent) than in
patients with atrophy [109]. In agreement, a recent study in
Sweden that analyzed more than 400000 patients concluded
that IM (independently of extent) significantly increases the
risk of gastric cancer. Interestingly, it showed that a second
endoscopic surveillance with biopsies can have significant
prognostic value, since downgrading of gastritis (to no IM de-
tected) is associated with less risk of progression to cancer
(and then these patients may not benefit from follow-up) [110].
Nevertheless, the prevalence of focal IM in the population
may be as high as 25% and it seems unreasonable to follow up
all of these patients [122]. Moreover, even though the present
authors recognize that focal IM may increase the risk of gastric
cancer compared to no IM or even to only atrophy, this risk ap-
pears too small to justify surveillance [19]. On the other hand,
extensive IM significantly increases the risk of gastric cancer
compared to focal IM, and in this scenario, surveillance is re-
commended.
Other factors may influence the risk for cancer:
Incomplete IM A Spanish prospective multicenter study
with a mean follow-up of 12 years found that incomplete IM
was associated with a significantly higher risk of gastric cancer
when compared with complete IM (HR 2.57, 95%CI 1.06–6.26)
[123]. A systematic review from the same authors also reported
that in 10 follow-up studies, incomplete type III IM was asso-
ciated with significantly higher risk of gastric cancer in 6 stud-
ies, with a 6–11-fold higher risk [124]. A recent study with a
follow-up of 16 years also showed that incomplete-type IM
was associated with a higher risk of progression to cancer than
the complete type (OR 11.3, 95%CI 1.4–91.4) [19]. These find-
ings suggest that incomplete IM is associated with a risk of pro-
gression similar to that attributed to extensive atrophy or fam-
ily history of gastric cancer. For these reasons, when reported,
this information can have prognostic value and can aid in the
selection of patients for surveillance. However, incomplete IM
is not always found in the gastrectomy specimens of gastric
cancer patients [125–127]. Additional studies are required be-
fore subtyping can be routinely recommended.
Family history Although most gastric cancers are sporadic,
some kind of familial aggregation occurs in 10% of cases [128].
Having a first-degree relative with gastric cancer is a consistent
risk factor for gastric cancer, with an odds ratio varying from 2
to 10 in relation to geographic region and ethnicity [129]. Im-
portantly, adjustment for environmental factors does not alter
this risk. Having a second-degree relative with gastric cancer
also confers a higher risk of development of the disease, but to
a lesser extent [130]. It is believed that this familial clustering of
gastric cancer is due to an inherited genetic susceptibility,
shared environmental or lifestyle factors, shared susceptibility
to H. pylori, sharing the same cytotoxic H. pylori strain, or a com-
bination of these factors. Accordingly, a meta-analysis showed
that first-degree relatives of gastric cancer patients have an in-
creased prevalence of H. pylori infection (OR 1.93), gastric atro-
phy (OR 2.2) and IM (OR 1.98) [131]. Also, first-degree relatives
of early-onset gastric cancer patients have increased prevalen-
ces of high stage gastritis (OLGA stage III/IV) and dysplasia that
seem to be associated with high virulence H. pylori strains and
pro-inflammatory host genotypes [68, 132].
Thus, these data show that first-degree relatives of gastric
cancer patients have an increased prevalence of H. pylori infec-
tion and precancerous conditions/lesions, as well as an in-
creased risk for gastric cancer.
Regarding progression of precancerous conditions, a US
study found an increased risk for progression in patients with
IM and a family history of gastric cancer (P=0.002) [116]. In an
Italian cohort, family history was also associated with a higher
risk for progression in patients with gastric atrophy although
this was not statistically significant [114]. Although there is
only scarce evidence that precancerous conditions in relatives
of a gastric cancer patient progress more rapidly through the
carcinogenic cascade to cancer than similar conditions in mat-
ched controls in a general population, it seems reasonable to
recommend a more intensive follow-up in patients with exten-
sive atrophy/IM and a first-degree family history of gastric
cancer.
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In sum, there is a significantly higher risk of progression to
cancer in patients with dysplasia, extensive atrophy/IM, and/or
OLGA/OLGIM stage III/IV, and we recommend endoscopic sur-
veillance of these patients, ideally by a high quality endoscopy.
However, the risk of gastric cancer is also increased, even
though with a lower magnitude, in patients with less advanced
stages of preneoplastic change, such as those with focal IM
(OLGIM I/II), particularly if there is also incomplete IM and/or a
family history of gastric cancer. There are also some practical
problems related to the adequate staging of precancerous con-
ditions in routine clinical practice, since an important propor-
tion of gastroscopies are performed with standard definition
WLE (nontargeted biopsies) and the adherence to biopsy proto-
cols is variable. We thus recommend (based on expert opinion)
that patients with only nonguided biopsies at the antrum show-
ing IM should be reassessed after 3 years with biopsies from an-
trum and corpus in separate vials, ideally with HD-NBI to allow
targeted biopsies and restaging, if this was not previously done.
If this high quality endoscopy excludes extensive IM then these
patients may be released from endoscopic surveillance. Excep-
tions may be cases of family history of gastric cancer, incom-
plete IM in biopsies, and persistent H. pylori.
The benefit of doing nontargeted biopsies in patients under
surveillance and already with correct staging of gastritis has not
been established. For this reason, for patients with an indica-
tion for surveillance we recommend a high quality endoscopy
with CE and biopsies of only the irregular/suspicious for dyspla-
sia areas with no further biopsies being needed (▶Fig. 2).
Regarding the schedule for surveillance, the MAPS I Guide-
line recommended, based on expert opinion, surveillance every
3 years in patients at higher risk for gastric cancer. A recent pro-
spective cohort study supports this recommendation, showing
a neoplasia risk of 36.5 per 1000 person-years in OLGA III pa-
tients (95%CI 13.7–97.4) and 63.1 per 1000 person-years in
High definition-chromoendoscopy (HD-CE) and guided biopsies OR 
at least 2 biopsies from the antrum and 2 from corpus, lesser and greater curvature 
Helicobacter pylori eradication if positive  
Surveillance preferentially with HD-CE with guided biopsies of irregular areasNo surveillance
Patients with atrophic gastritis or intestinal metaplasia (IM) Patients with dysplasia
Endoscopic reassessment at a reference center with HD-CE
Yes
Yes
No
No4
YesNo
Visible lesion?
HD-CE in 6months (high grade dysplasia) 
to 12months (low grade dysplasia)
If no visible lesion (re)stage gastritis and 
follow up accordingly
Staging and 
resection
Every yearEvery 1–2yearsEvery 3years
Mild to moderate 
atrophy only in 
the antrum, no IM
IM only in the 
antrum OR IM 
only in the corpus
Atrophy OR IM  in 
both antrum and 
corpus1
Family history of gastric 
cancer2, incomplete IM3, 
autoimmune gastritis, or 
persistent H. pylori infection
First-degree 
family history of 
gastric cancer2
▶ Fig. 2 Proposed management for patients with atrophic gastritis, gastric intestinal metaplasia, or gastric epithelial dysplasia. OLGA, Operative
Link on Gastritis Assessment; OLGIM, Operative Link on Gastritis Assessment based on Intestinal Metaplasia.
1Advanced stages of atrophic gastritis warranting surveillance should be defined as significant (moderate to marked) atrophy or intestinal
metaplasia (IM) affecting both antral and corpus mucosa or as OLGA/OLGIM stages III/IV. Mild atrophy without IM, even when affecting antrum
and corpus, should not be considered to be an advanced stage of gastritis.
2First-degree family history of gastric cancer is an important risk factor for gastric cancer and even though the evidence is scarce these patients
may benefit from a more intensive follow-up. These recommendations do not apply to hereditary/familial diffuse gastric cancer.
3When reported, incomplete IM may identify patients with a higher risk of gastric cancer. However, additional studies are required before
subtyping can be routinely recommended.
4After diagnosis of dysplasia, revision of pathology slides by an expert gastrointestinal pathologist should be considered, particularly when no
lesion is seen after a high quality endoscopy. If expert revision does not confirm the diagnosis of dysplasia then the patient may be released from
intensive follow-up.
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OLGA IV patients (95%CI 20.3–195.6) [133]. The authors sug-
gested that the best follow-up surveillance interval would be 2
instead of 3 years. However, the cost-effectiveness of a 2-year
interval for every patient may not be ideal and the evidence is
not strong enough to change the recommended 3-year surveil-
lance interval. Nevertheless, the present authors recognize that
patients with extensive IM, and also with at least one of persist-
ent H. pylori infection, incomplete IM, or, particularly, a first-de-
gree family history of gastric cancer, may benefit from a tighter
endoscopic surveillance schedule (e. g. every 1 –2 years). These
recommendations do not apply to hereditary/familial diffuse
gastric cancer, for which there are specific guidelines [134].
5.3 Autoimmune gastritis
Autoimmune gastritis is a chronic progressive inflammatory
condition that results in the replacement of the parietal cell
mass by atrophic and metaplastic mucosa, leading to a corpus-
predominant atrophic gastritis, reduced or absent acid produc-
tion, and loss of intrinsic factor which may progress to a severe
form of vitamin B12-deficiency anemia known as pernicious
anemia. Both gastric carcinoma and neuroendocrine tumors
are the most dreaded long-standing complications of perni-
cious anemia.
Most of the evidence on the risk of gastric cancer associated
with pernicious anemia comes from case-control [135, 136]
and cohort studies [114, 137–144]. One study based on the
Surveillance, Epidemiology, and End Results (SEER) database
compared 1138390 pernicious anemia cases to 100000 mat-
ched individuals [135]. Individuals with pernicious anemia
were at increased risk for noncardia gastric adenocarcinoma
(OR 2.18, 95%CI 1.94–2.45) and gastric carcinoid tumors (OR
11.43, 95%CI 8.90–14.69). However, the diagnosis of auto-
immune gastritis in this study was rather flawed as it was solely
based on low levels of vitamin B12 [145]. Therefore, many of
the patients supposedly with autoimmune gastritis probably
had other causes of low serum vitamin B12, and the risk of can-
cer for genuine autoimmune gastritis patients was likely under-
estimated. A Swedish study followed 21 265 patients with per-
nicious anemia for an average of 7.1 years [138]. These patients
had a significant excess risk for gastric cancer distal to the car-
dia (standardized incidence ratio [SIR] 2.4, 95%CI 2.1–2.7).
The excess risks increased with increasing follow-up duration.
Among distal gastric cancers, the most conspicuous excess risk
was for carcinoid tumors (SIR 26.4, 95%CI 14.8–43.5). The
abovementioned criticism with respect to the diagnosis of
autoimmune gastritis also pertained to this study.
A recent meta-analysis with 27 studies and a total of 22417
patients showed that the calculated pooled gastric cancer inci-
dence rate was 0.27% per person-year and the overall gastric
cancer relative risk in pernicious anemia was 6.8 (95%CI 2.6–
18.1) [146]. The drawback of this meta-analysis is again that
many patients included in these studies may have had low vita-
min B12 serum levels because of conditions other than auto-
immune gastritis.
Therefore, there is some evidence suggesting that auto-
immune gastritis is a precancerous condition that may justify
endoscopic monitoring. Nevertheless, there is no recommen-
ded follow-up interval to date.
Since the largest excess risk of gastric cancer incidence
among patients with pernicious anemia has been found during
the first year of follow-up [141, 143], there is evidence to re-
commend endoscopic screening to all patients at the time of
the diagnosis.
Several cohort studies prospectively evaluated the risk of
gastric cancer in patients with pernicious anemia, with varying
follow-up intervals from 3 to 7 years [114, 139, 140, 142, 147–
149]. One study [147] performed follow-up gastroscopies
3 years after primary screening examination of 56 patients and
identified on follow-up 2 patients with gastric adenocarcinoma,
no patient with HGD, and 49 patients with IM. Another study
[142] followed up a group of 27 patients for 6 to 7 years after
initial investigation. None of the patients had developed gastric
cancer since the initial endoscopy and the distribution of dys-
plasia was virtually unchanged. The only randomized controlled
trial (RCT) to determine the most effective time interval for the
first follow-up endoscopy after diagnosis of corpus-predomi-
nant atrophic gastritis randomly assigned 24 patients to a 24-
or 48-month follow-up interval [148]. No gastric cancer was
found in either group, but a patient from the 48-month group
developed a neuroendocrine tumor. The authors concluded
that the first follow-up need not be earlier than 4 years after
diagnosis, with this interval being satisfactory for detection of
potential neoplastic lesions. Considering the heterogeneity of
the described cohorts and the absence of larger RCTs with long-
er follow-up, we recommend follow-up endoscopy at 3- to 5-
year intervals in patients with autoimmune gastritis.
6 Therapy
6.1 Helicobacter pylori eradication
RECOMMENDATION
19 Patients with autoimmune gastritis may benefit from
endoscopic follow-up every 3–5 years.
Low quality evidence, weak recommendation (82% agree
[76% strongly or moderately agree]).
RECOMMENDATION
20 H. pylori eradication heals nonatrophic chronic gastri-
tis, may lead to regression of atrophic gastritis, and re-
duces the risk of gastric cancer in patients with
nonatrophic and atrophic gastritis, and, therefore, it is
recommended in patients with these conditions.
High quality evidence, strong recommendation (87%
agree [87% strongly or moderately agree]).
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Since publication of the MAPS I Guideline, three meta-
analyses have been performed regarding the effect of H. pylori
eradication on chronic gastritis and risk of gastric cancer [150–
152]. The first meta-analysis included only prospective trials
and RCTs on H. pylori eradication with a focus on histology (be-
fore and after treatment) and not on the risk of gastric cancer
[151]. The authors concluded that IM in the antrum and atroph-
ic gastritis in both the antrum and corpus regressed after eradi-
cation of H. pylori, although this effect was not seen for IM in
the corpus. This meta-analysis was statistically more powerful
than previous ones on this subject and strongly suggests that
H. pylori eradication halts progression of precancerous condi-
tions even after IM has appeared. In fact, when studies with a
longer follow-up (> 5 years) and with larger groups are ana-
lyzed, they do show a statistical improvement for IM both at
the antrum and at the corpus after H. pylori eradication therapy
has been received [19, 153–155]. One study even showed no
statistically significant difference with regard to IM in compari-
son to an H. pylori-negative group, for the corpus 3 years after
H. pylori eradication and for the antrum 5 years after H. pylori
eradication [153]. Despite the possibility of sampling error, it
appears logical that for a lesion that occurs after decades of in-
fection, reversion also only occurs after a very long period and
the risk of gastric cancer may also only decrease in the long but
not the short term.
Both meta-analyses that focused on the risk of gastric cancer
after H. pylori eradication concluded that H. pylori eradication
significantly decreases the risk of gastric cancer in patients
with chronic atrophic or nonatrophic gastritis (pooled relative
risk [RR] 0.64, 95%CI 0.48–0.85) but not in patients with IM
or dysplasia (RR 0.88, 95%CI 0.59–1.31) [150, 152]. However,
only a few of the studies included in these meta-analyses had a
long follow-up period (more than 10 years).
In conclusion, there is strong evidence suggesting that H. py-
lori eradication is highly beneficial in patients with chronic non-
atrophic and atrophic gastritis, both histologically and in redu-
cing gastric cancer risk. At later stages of gastritis (established
IM) weaker evidence suggests that H. pylori eradication has
beneficial histological effects, with no conclusive effect,
however, on gastric cancer risk reduction. Nevertheless, no
study suggested that H. pylori eradication has negative effects
on patients with IM and, so, considering the positive histologi-
cal effects of H. pylori eradication, it is the opinion of the pres-
ent authors that H. pylori eradication should also be offered to
patients with IM. It is also important to note that H. pylori infec-
tion is now considered an infectious disease and eradication is
recommended in most cases, regardless of the presence of pre-
cancerous conditions [156].
There is also controversy about H. pylori eradication therapy
after endoscopic removal of gastric superficial neoplasia. After
publication of the MAPS I Guideline, a multicenter retrospective
study including six Japanese centers and 268 patients contra-
dicted its recommendation in favor of such treatment [157]. In
that study, even though metachronous gastric cancer devel-
oped in 14.3% versus 8.5% of the patients of the H. pylori-per-
sistent vs. the H. pylori-eradicated group, the baseline severity
of mucosal atrophy and a follow-up of more than 5 years were
the only independent risk factors for metachronous neoplasia
[157]. A prospective RCT that included 901 patients failed to
show that H. pylori eradication reduced the risk of metachro-
nous lesions (2.2% treated vs. 3.7% nontreated, P=0.15)
[158]. This trial contradicted another previously published RCT
on this subject that showed a significant reduction of gastric
cancer in H. pylori-eradicated patients [159]. Moreover, in
another retrospective study that included 2089 patients who
underwent endoscopic resection of a superficial lesion, the in-
cidence of metachronous gastric cancer was 10.9 cases per
1000 person-years in the H. pylori-negative group, 14.7 cases
per 1000 person-years in the H. pylori-eradicated group, and
29.7 cases per 1000 person-years in the group without H. pylori
eradication (HR 1.9 when compared to H. pylori-eradicated
group, P=0.02) [160]. Two meta-analyses on this subject in-
cluded the same 10 studies (8 nonrandomized, 2 randomized),
but with 5914 and 5881 patients because of different inclusion
criteria. They reached the identical conclusion that H. pylori era-
dication reduces the risk of metachronous lesions with a risk
ratio of 0.467 (95%CI 0.362–0.602; P <0.001) [161, 162]. Final-
ly, a 2018 double-blind, placebo-controlled RCT that included
396 patients in the intention-to-treat analysis conclusively
showed that H. pylori eradication in this group of patients re-
duced the risk of metachronous lesions to almost half (7% vs.
13%; HR 0.5, 95%CI 0.26–0.94) [163].
In summary, H. pylori eradication has the largest impact on
gastric cancer risk in patients with nonatrophic gastritis and
early stages of atrophy. Nevertheless, a small benefit of eradica-
tion is still seen at later stages of gastritis and even after resec-
tion of a lesion. For this reason, we recommend that H. pylori
eradication should always be considered.
RECOMMENDATION
21 In patients with established IM, H. pylori eradication
does not appear to significantly reduce the risk of gastric
cancer, at least in the short term, but reduces inflamma-
tion and atrophy and, therefore, it should be considered.
Low quality evidence, weak recommendation (87% agree
[75% strongly or moderately agree]).
RECOMMENDATION
22 H. pylori eradication is recommended for patients with
gastric neoplasia after endoscopic therapy.
High quality evidence, strong recommendation (100%
agree [100% strongly or moderately agree]).
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6.2 Other therapies
COX inhibitors Earlier meta-analyses (2003, 2010) had sug-
gested a lower risk of gastric cancer in users of COX-inhibitors
[164, 165]. Since the publication of MAPS I, few studies have
specifically addressed this issue but all added evidence sup-
porting this position. In 2013, a prospective nonrandomized
study reported on the role of selective COX-2 inhibitor treat-
ment in patients with precancerous gastric conditions: after
1 year of treatment with celecoxib following H. pylori eradica-
tion, IM regression was more frequent in the treatment versus
the control group (44.3% vs. 14.3%, total 140 patients) [166].
Other studies suggest that inhibition of COX may slow progres-
sion of gastric precancerous conditions and in theory may de-
crease the risk of gastric cancer development. A double-blind
RCT, including 1024 participants who received H. pylori era-
dication treatment or placebo followed by celecoxib or placebo
(i. e., four different groups studied), showed that regression of
gastric precancerous conditions significantly increased both in
the eradication group (59% vs. 41% placebo) and in the cele-
coxib group (53% vs. 41% placebo) with an OR of 1.72 (95%CI
1.07–2.76) for celecoxib and 2.19 (95%CI 1.32–3.64) for H. py-
lori eradication [167]. However, in this study no statistically sig-
nificant benefit was observed for celecoxib after H. pylori eradi-
cation. Moreover, 9 cancers developed in this study but it was
underpowered to show a therapeutic benefit of any strategy.
Nonsteroidal anti-inflammatory drugs (NSAIDs) Several
meta-analyses investigating the role of aspirin and other
NSAIDs on the risk of gastric cancer have accumulated, all of
them showing a favorable effect [168–173]. In the most recent
meta-analysis, which included 24 studies, both nonaspirin
NSAIDs (RR 0.86, 95%CI 0.80–0.94) and aspirin (RR 0.70, 95%
CI 0.62–0.80) significantly reduced noncardia gastric cancer
risk [168]. However, the vast majority of original studies did
not include patients with precancerous gastric conditions.
Moreover, the protective effect of aspirin/NSAIDs was more
marked for noncardia gastric cancer and in H. pylori-positive in-
dividuals. In fact, when only H. pylori-negative patients were
considered, the effect of aspirin was nonsignificant (RR 0.81,
95%CI 0.52–1.26). In sum, evidence suggests that NSAIDs
may slow down the progression of gastric precancerous condi-
tions. However, this effect is small and eventually nonsignifi-
cant after H. pylori eradication or in more advanced lesions.
Considering that NSAIDs have a potential for serious adverse
events it is the opinion of the present authors that they cannot
be recommended specifically for this purpose. The exception
may be low dose aspirin since it has a better safety profile and
its beneficial effects are more generalized, reducing also cardi-
ovascular death risk and the risk of development of other can-
cers, and therefore it could be considered in selected patients.
Rebamipide and moluodan The effects of two other drugs
on pathological findings has been investigated; the drugs were
administered for 6–12 months following H. pylori eradication
therapy if required. Rebamipide, a free-radical scavenger, re-
duced inflammation, IM, and LGD in one RCT [174], and re-
duced chronic inflammation but not IM in another RCT [175];
the RCTs included a total of 280 patients. Moluodan, a prepara-
tion of Chinese medicine herbs, was associated with a decrease
in the dysplasia score, with dysplasia disappearance reported in
24.6% of patients in an RCT (196 patients) [176]. Future studies
should confirm these results before any recommendation can
be made regarding these therapies.
Antioxidant vitamins With respect to antioxidant vitamin
supplementation, no new studies evaluating their effects on
gastric precancerous conditions were identified. In the general
population, intake of some vitamins may decrease the risk of
gastric cancer (RR 0.77, 95%CI 0.71–0.83) according to a
meta-analysis of 47 studies including 1221392 participants
[177]. A significant risk reduction of approximately one third
was found for vitamins A, C, and E at daily doses of 1.5mg,
100mg, and 10mg, respectively. The risk reduction was noted
only in studies where low dose dietary vitamins were used, not
when vitamins were administered at high dose or as a drug sup-
plement. Some authors have suggested that an efficient inter-
vention would aim at nutrient repletion (i. e., with physiological
as opposed to pharmacological doses) in high risk populations
with poor nutrition [178]. Regarding potential harm, a meta-
analysis (53 RCTs, 241883 participants) found that supplemen-
tation with vitamins A and E in doses higher than the recom-
mended daily allowances (as used in some of the studies includ-
ed in the abovementioned meta-analysis [177]) were associat-
ed with increased mortality [179].
In line with this, two meta-analyses found a twofold higher
risk of gastric cancer in individuals consuming low versus high
amounts of allium vegetables [180], and in those consuming a
“Western/unhealthy” diet, rich in starchy foods, meat, and fats,
versus a “prudent/healthy” diet rich in fruits and vegetables
[181].
RECOMMENDATION
24 Low dose daily aspirin may be considered for preven-
tion of various cancers, including gastric cancer, in select-
ed patients.
Moderate quality evidence, weak recommendation (94%
agree [47% strongly or moderately agree]).
RECOMMENDATION
23 Even though cyclo-oxygenase (COX)-1 or COX-2 inhi-
bitors may slow progression of gastric precancerous con-
ditions, they cannot be recommended specifically for this
purpose.
Low quality evidence, weak recommendation (100%
agree [94% strongly or moderately agree]).
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7 Cost-effectiveness of surveillance and
screening
Surveillance of precancerous conditions In 2012 when
the MAPS I Guideline was issued, three studies had been pub-
lished regarding the cost-effectiveness of surveillance of pre-
cancerous conditions. They had provided conflicting results,
mainly because of different estimates for progression to dys-
plasia or cancer. Since then only three further studies have
been published, all in intermediate risk countries.
Areia et al. used a Markov model for Portugal, comparing the
cost-utility of three different endoscopic surveillance strate-
gies, every 3, 5, or 10 years, for patients with extensive precan-
cerous conditions aged 50–75 years [182]. It showed that
endoscopic surveillance of patients with extensive precancer-
ous conditions every 3 years was cost-effective compared to
no surveillance and was better than the 5- and 10-year strate-
gies.
Zhou et al. also applied a Markov model in Singapore and
compared the cost-utility of several endoscopic surveillance or
screening strategies, every 1 or 2 years, for patients aged 50–
69 [183]. It showed that endoscopic surveillance of patients
with precancerous conditions every 2 years was the most cost-
effective strategy while screening strategies were extendedly
dominated (i. e., had a lower incremental cost-effectiveness or
were cost-ineffective).
A third cost-utility model from Wu et al., also for Singapore,
compared endoscopic surveillance every 1 year versus endo-
scopic screening every 2 years versus nothing, for patients
aged 50–69, and concluded that annual endoscopic surveil-
lance was cost-effective for patients with precancerous condi-
tions [184].
All three models demonstrated that endoscopic surveillance
of patients with precancerous conditions in countries with an
intermediate risk for gastric cancer was cost-effective, as sug-
gested by the MAPS I Guideline. The recommended 3-year in-
terval was specifically modelled only in the study from Portugal
and proved to be better than longer 5- or 10-year intervals,
while the studies from Singapore showed that a 1- or 2-year in-
terval was most suitable but did not model the 3-year option.
In conclusion, endoscopic surveillance every 3 years of pa-
tients with precancerous conditions in countries with an inter-
mediate risk for gastric cancer is cost-effective, but further eco-
nomic studies would be welcome to further define the optimal
interval for endoscopy.
Endoscopic screening for gastric cancer. Regarding endo-
scopic screening for gastric cancer in the general population, at
present it is applied only in high risk populations, such as those
of Japan and Korea, and several economic studies have already
been published proving its cost-effectiveness [185].
Since 2012, two further studies have been published for the
Korean population, again concluding that endoscopic screen-
ing for this high risk population is cost-effective. Chang et al.,
using a cost-utility model from a societal perspective for the
population aged 50–80 years, concluded that endoscopic
screening annually for men and biennially for women was the
optimal cost-effective option among 12 different strategies
[186]. Another cost-effectiveness model, also from a societal
perspective in patients older than 40 years, demonstrated that
annual endoscopic screening was better than X-ray screening
or no screening [187].
Regarding the cost-effectiveness of endoscopic screening
for gastric cancer in intermediate or low incidence countries,
three models have been published since preparation of the
MAPS I Guideline. Yeh et al. investigated a one-time gastric
cancer screening strategy for an American population at age
50, with a cost-utility analysis from a societal perspective, com-
paring serum pepsinogen test screening followed by endoscopy
if results were positive versus endoscopic screening; they con-
cluded that for this low risk population neither option was cost-
effective [188]. Others also used a Markov cost-utility model for
the US population, and analyzed the option of adding a one-
time screening upper endoscopy at the time of screening colo-
noscopy in 50-year-old patients. They concluded that this op-
tion was not cost-effective for this low risk population despite
the reduced endoscopy costs [189]. Finally, Areia et al. model-
led the option of adding a screening upper endoscopy at the
time of screening colonoscopy, in Portugal, an intermediate to
high risk country for gastric cancer [190]. Using a Markov cost-
utility analysis they compared three screening strategies:
stand-alone upper endoscopy, endoscopy combined with a
colorectal cancer screening colonoscopy after a positive fecal
occult blood test, or pepsinogen serology screening. The con-
clusion was that endoscopic gastric cancer screening was cost-
effective if combined with a screening colonoscopy in Portugal.
Furthermore, this strategy might prove to be cost-effective in
other European countries with a gastric cancer risk ≥10 per
100000 inhabitants, depending on further specific economic
studies for each local setting.
8 Research agenda
During the updating of this Guideline, gaps in evidence re-
mained noticeable. Further research is needed, including:
▪ Large randomized trials with different surveillance
schedules, that would elucidate the natural history of each
stage of gastric changes (and identify further variables for
predicting progression), and also clarify the benefit of each
surveillance interval;
▪ Adequately designed trials to assess the effect of interven-
tions such as H. pylori eradication and others regarding the
premalignant stomach;
▪ Studies to address methodologies and target populations for
screening these lesions in Western countries.
RECOMMENDATION
25 In intermediate to high risk regions, identification and
surveillance of patients with precancerous gastric condi-
tions is cost-effective.
Moderate quality evidence) (100% agree [94% strongly or
moderately agree]).
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Disclaimer
The legal disclaimer for ESGE guidelines [191] applies to the
current Guideline.
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